Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 9/20 | 0.42 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.41 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.37 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25318628 | 0.88 | TNF (0.41) | TNFPSMB5PSMB1HDAC3HDAC1 | |
| SCHEMBL30550660 | 0.82 | TNF (0.38) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25899466 | 0.81 | TNF (0.39) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25320463 | 0.81 | PTPN1 (0.38) | TNFAAK1PSMB5PSMB1 | |
| SCHEMBL25320458 | 0.81 | PTPN1 (0.38) | TNFAAK1PSMB5PSMB1 | |
| SCHEMBL25318213 | 0.79 | AAK1 (0.36) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25318208 | 0.79 | AAK1 (0.36) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25322149 | 0.79 | AAK1 (0.38) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25322154 | 0.79 | AAK1 (0.38) | TNFAAK1PSMB5PSMB1HDAC3 | |
| SCHEMBL25320533 | 0.78 | TIPARP (0.40) | TNFAAK1PSMB5PSMB1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | GILEAD SCIENCES, INC. (US) | 2025-11-04 | — | — | US | disclosed |
| EP-4469448-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2024-12-04 | — | — | EP | disclosed |
| US-20230365529-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147418-A1 | PARP7 INHIBITORS | GILEAD SCIENCES, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459922-B2 | PARP7 inhibitors | PARP1, PARP11, PARP2 | TNF 4831/4885AAK1 2312/4885PSMB5 1412/4885 |
| US-20230365529-A1 | PARP7 INHIBITORS | PARP1, PARP11, PARP2 | TNF 4831/4885AAK1 2312/4885PSMB5 1412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.